The Global Virus Network (GVN), representing eminent human and animal virologists from more than 90 Centers of Excellence and Affiliates in over 40 countries dedicated to advancing research, ...
Hosted on MSN
New cicada Covid-19 variant BA.3.2 detected in the US: Key facts, symptoms, risk factors explained
A newly identified Covid-19 subvariant, BA.3.2, informally dubbed the "Cicada" variant, is drawing global attention after being detected in the United States and other regions. Emerging from the ...
TAMPA, FL, USA (April 3, 2026) – The Global Virus Network (GVN), representing eminent human and animal virologists from more than 90 Centers of Excellence and Affiliates in over 40 countries dedicated ...
SARS-CoV-2 possesses a characteristic surface protein, the spike protein, which plays a central role in viral entry into host cells. The evolution of spike protein mutations has been an important ...
The SARS-CoV-2 variant BA.3.2 spread slowly before being detected in at least 23 countries in five continents by February. The prevalence of BA.3.2 was 0.55% among 5,238 U.S. samples collected from ...
An international research team has identified a previously overlooked factor that influences how antibodies neutralize SARS-CoV-2: their mechanical stability under force. Antibodies are key components ...
A SARS-CoV-2 subvariant called BA.3.2, carrying a significant genomic deletion and mutations linked to immune evasion, has been detected among travelers arriving in the United States. The variant, ...
BA.3.2 spread internationally after first being identified in South Africa in November 2024, with detections rising from September 2025 and reports from at least 23 countries by 11 February 2026. U.S.
Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...
CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results